Nike just broke out of an algorithmic downward channel. And it's up HUGE!
Everyone dumped Merck last week during quarter-end window dressing. It's one of my core holdings.
Pfizer got a three-year grace period from tariffs and price controls. Look at it today.
No one loved these stocks.
What changed?
The calendar flipped to October 1st.
For three months, you watched sacred cows get bought on every dip regardless of valuation.
You saw fundamental analysis fail. Technical indicators became useless.
Portfolio managers couldn't let winners drag down quarterly numbers, so algorithms bought strength no matter how overbought conditions became.
Now that programming is over. Window dressing season ended yesterday.
The machines controlling 90% of daily volume are now operating under completely different parameters. What worked in September will destroy accounts in October.
Here's what you need to understand about the rotation that just started—and why the stocks everyone dumped last month are about to make serious money.
The Quarter-End Game That Controls Billions
Portfolio managers face quarterly performance reviews. These reviews determine their careers.
They cannot show clients declining positions on September 30th statements. Can't do it.
This creates artificial buying pressure on momentum stocks. Forced selling on underperformers.
Money managers hide losing positions. They showcase only winners during quarter-end reporting.
They might hold 200 stocks but display only 40 on client presentations.
I watched General Mills get hammered despite an analyst upgrade. Algorithmic baskets sold it down 3% in the opening hour.
Someone needed it gone before October 1st.
Meanwhile, overvalued growth stocks got relentless buying. Not because fundamentals improved.
Because fund managers couldn't afford to miss the biggest winners when clients reviewed quarterly statements.
The algorithms follow programming that prevents major selling until the quarter ends. They literally cannot execute systematic rotations while institutional window dressing continues.
Every dip gets bought. Every single one.
Fund managers need their winners to stay strong for reporting.
When that programming shifts on October 1st, everything changes. Instantly.
What the Rotation Looks Like Right Now
I've been holding Merck for months. Bought it around $77.
Watched it get dumped during September window dressing while everyone chased momentum stocks.
Didn't care. The valuation was there.
Merck trades at 12 times earnings. The company just got approval for two blockbuster drugs.
Compare that to Reddit at 94 times earnings. Or DoorDash at 1,000 times earnings with 10% growth.
The setup was textbook:
- Undervalued fundamentals institutions couldn't ignore forever
- Window dressing creating artificial selling pressure
- Technical patterns showing institutional accumulation behind the scenes
- Trump administration giving pharma a grace period on tariffs and price controls
Today Merck ripped higher.
Not because I'm a genius. Because the quarterly constraints disappeared. Algorithms could finally rotate into value.
The same pattern is playing across multiple sectors. Right now.
Pharma getting bought aggressively. Pfizer, Bristol Myers, AstraZeneca all breaking out.
Overvalued momentum getting sold. Stocks that rode window dressing higher are now vulnerable.
Energy showing strength. Devon Energy, Schlumberger forming bullish patterns.
Retail getting hammered. Costco, Walmart, Target facing selling pressure.
This isn't random. This is systematic rotation driven by algorithms operating under new monthly parameters.
The Stocks That Killed You in September Will Make Money in October
Pharma has been the most hated sector for months.
I've never seen drug stocks cheaper in my 37-year career. Nobody's ever seen pharmas trading at PEs of 12 times earnings.
Nobody.
While everyone chased AI stocks and momentum plays, I was accumulating pharmaceutical companies. Trading at absurd discounts.
Not because I'm smarter than the market. Because I understand how quarterly programming works.
The window dressing that forced selling pressure on these names just ended. Now fundamentals matter again.
Algorithms can finally position in undervalued stocks. No more fighting quarterly reporting constraints.
Pfizer got a three-year grace period from Trump. No tariffs. No price controls.
As long as drugs are manufactured in the US.
That's not a rumor. That's policy driving institutional accumulation.
Merck raised guidance with two blockbuster drugs in the pipeline. The company's fundamentals improved while window dressing forced the stock lower.
Perfect setup for October rotation.
AstraZeneca moved its listing from NASDAQ to the Big Board. Creating institutional sponsorship and liquidity that drives systematic buying.
Up $4 before the breast cancer news even hit.
Your October Trading Rules
The market you traded for the last three months no longer exists.
Take everything you learned in July, August, and September and erase it. Gone.
Stop chasing momentum that worked in September. Those trades are over.
Reddit at 94 times earnings becomes a trap when algorithms switch from buying to selling. The same vertical runs that made money on the way up will destroy accounts on the way down.
Start looking at what got dumped during window dressing. Undervalued stocks with strong fundamentals that portfolio managers needed to hide from quarterly statements.
These become systematic buys when quarterly constraints disappear.
Pay attention to sector rotations. Not index levels.
The S&P obfuscates everything. Individual stocks can decouple and run while the index sits flat.
That's where money gets made.
Fundamentals matter again. But only on the way down.
Overvalued momentum stocks become vulnerable when algorithms can finally sell without quarterly reporting pressure.
On the way up, fundamentals don't matter. On the way down, they're the difference between taking profits and watching gains evaporate.
The Algorithmic Edge
Algorithms calculate quarterly programming shifts before executing trades.
They know when portfolio managers face reporting constraints. They know when those constraints disappear.
The machines aren't guessing about October rotations. They're following mathematical parameters that reset on the first day of each quarter.
While retail traders wonder why their momentum plays suddenly reversed, algorithms are already positioned for the next three months.
This is why I bought Merck months ago at $77. Held through September's window dressing selloff.
The quarterly rotation was predictable. The timing was known.
The only question was whether traders would position for it or fight against it.
Your account performance in October depends on one decision.
Will you trade the market that just ended, or the market that just started?
The algorithms already made their choice.
Ready to Take the Next Step?
The Genesis Cog system tracks these quarterly programming shifts in real time. Revealing when algorithmic buying pressure changes to selling pressure and vice versa.
It shows you which stocks face artificial window dressing pressure versus genuine fundamental deterioration. The difference between buying opportunities and value traps.
Stop fighting quarterly rotations you can't see.
Professor Jeffrey Bierman
Creator of the Genesis COG System